Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
95 studies found for:    hedgehog
Show Display Options
Rank Status Study
1 Recruiting Study of Vismodegib in Combination With Temozolomide Versus Temozolomide Alone in Patients With Medulloblastomas With an Activation of the Sonic Hedgehog Pathway
Conditions: Histologically Confirmed Medulloblastoma;   Activation of the Sonic Hedgehog (SHH) Pathway
Interventions: Drug: vismodegib;   Drug: Temozolomide
2 Terminated Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative Setting (HIPPoS)
Condition: Pancreatic Ductal Adenocarcinoma
Intervention: Drug: GDC-0449
3 Recruiting Itraconazole as a Targeted Therapy for Inhibiting Hedgehog Pathway Signaling in Esophageal Cancer Patients
Condition: Esophageal Cancer
Intervention: Drug: Itraconazole
4 Recruiting LDE225 in Patients With Advanced or Metastatic Hepatocellular Carcinoma and Child-Pugh A/B7 Cirrhosis
Conditions: Hepatocellular Carcinoma;   Cirrhosis
Intervention: Drug: LDE225
5 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) With Concurrent Chemotherapy and Bevacizumab As First-Line Therapy for Metastatic Colorectal Cancer
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib;   Drug: Bevacizumab;   Drug: Modified FOLFOX;   Drug: FOLFIRI
6 Unknown  Preliminary Study of Sonic Hedgehog Signaling Pathway in the Pathogenesis of Rheumatoid Arthritis
Conditions: Arthritis, Rheumatoid;   Neovascularization, Pathologic;   Synovitis
Intervention:
7 Active, not recruiting Hedgehog Inhibitors for Metastatic Adenocarcinoma of the Pancreas
Condition: Metastatic Pancreatic Cancer
Intervention: Drug: Gemcitabine, nab-Paclitaxel, GDC-0449
8 Active, not recruiting
Has Results
A Randomized Phase II Study of Cisplatin and Etoposide in Combination With Either Hedgehog Inhibitor GDC-0449 or IGF-1R MOAB IMC-A12 for Patients With Extensive Stage
Conditions: Extensive Stage Small Cell Lung Carcinoma;   Recurrent Small Cell Lung Carcinoma
Interventions: Drug: Cisplatin;   Biological: Cixutumumab;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Vismodegib
9 Recruiting PF-04449913 For Patients With Acute Leukemia at High Risk of Relapse After Donor Stem Cell Transplant
Conditions: Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia
Intervention: Drug: Hedgehog inhibitor PF-04449913
10 Withdrawn A Biomarker Study to Identify Predictive Signatures of Response to LDE225 (Hedgehog Inhibitor) In Patients With Resectable Pancreatic Cancer
Condition: Pancreatic Ductal Adenocarcinoma
Intervention: Drug: LDE225
11 Completed
Has Results
A Study of Hedgehog Pathway Inhibitor GDC-0449 in Patients With Locally Advanced or Metastatic Solid Tumors That Are Refractory to Standard Therapy or for Whom No Standard Therapy Exists
Condition: Solid Cancers
Intervention: Drug: GDC-0449
12 Recruiting Interrogation of Wnt, Notch and Hedgehog Activity in Primary Tumor Samples
Condition: Cancer
Intervention:
13 Completed A Study Of PF-04449913 In Select Hematologic Malignancies
Condition: Hematologic Malignancies
Intervention: Drug: PF-04449913
14 Completed
Has Results
A Study of Vismodegib (GDC-0449, Hedgehog Pathway Inhibitor) As Maintenance Therapy in Patients With Ovarian Cancer in a Second or Third Complete Remission
Condition: Ovarian Cancer
Interventions: Drug: Vismodegib 150 mg;   Drug: Placebo to vismodegib
15 Recruiting Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AML
Condition: Acute Myeloid Leukemia
Interventions: Drug: Ribavirin;   Drug: Vismodegib;   Drug: Decitabine
16 Withdrawn A Pilot Study of a Hedgehog Pathway Inhibitor (LDE-225) in Surgically Resectable Pancreas Cancer
Condition: Resectable Pancreatic Cancer
Intervention: Drug: LDE-225
17 Completed Pilot Study of Cetuximab and the Hedgehog Inhibitor IPI-926 in Recurrent Head and Neck Cancer
Condition: Recurrent Head and Neck Cancer
Intervention: Drug: IPI-926 and Cetuximab
18 Recruiting Wnt, Notch and Hedgehog Activity in Chemo-Naive Tumors Collected During Staging of Esophageal Cancer Patients
Condition: Esophageal Cancer
Intervention: Procedure: Tumor Biopsy via Ultrasound Endoscopy
19 Completed A Study of the Hedgehog Pathway Inhibitor GDC-0449 in Healthy Female Subjects of Non-Childbearing Potential
Condition: Healthy
Intervention: Drug: GDC-0449
20 Active, not recruiting Combination of the Hedgehog Inhibitor, LDE225, With Etoposide and Cisplatin in the First-Line Treatment of Patients With Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Condition: Lung Cancer
Intervention: Drug: LDE225, Etoposide and Cisplatin

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.